Beam Therapeutics Inc.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a BEAM research report →
Companywww.beamtx.com
Beam Therapeutics Inc. , a biotechnology company, develops precision genetic medicines for patients suffering from serious diseases in the United States. The company is developing BEAM-101 for the treatment of sickle cell disease and beta thalassemia; BEAM-102 for the treatment of sickle cell disease; and BEAM-201, an allogeneic chimeric antigen receptor T cell for the treatment of relapsed/refractory T-cell acute lymphoblastic leukemia; and BEAM-301, a liver-targeted development candidate for the treatment of patients with Glycogen Storage Disease Type Ia.
- CEO
- John Evans
- IPO
- 2020
- Employees
- 393
- HQ
- Cambridge, MA, US
Price Chart
Valuation
- Market Cap
- $2.79B
- P/E
- -43.04
- P/S
- 17.01
- P/B
- 2.40
- EV/EBITDA
- -43.82
- Div Yield
- 0.00%
Profitability
- Gross Margin
- -32.43%
- Op Margin
- -226.58%
- Net Margin
- -39.66%
- ROE
- -5.89%
- ROIC
- -26.15%
Growth & Income
- Revenue
- $139.74M · 120.01%
- Net Income
- $-79,992,000 · 78.77%
- EPS
- $-0.81 · 82.31%
- Op Income
- $-383,693,000
- FCF YoY
- -1.08%
Performance & Tape
- 52W High
- $36.44
- 52W Low
- $15.35
- 50D MA
- $27.69
- 200D MA
- $25.60
- Beta
- 2.26
- Avg Volume
- 2.15M
Get TickerSpark's AI analysis on BEAM
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Recent Insider Transactions
| Date | Insider | Type | Shares |
|---|---|---|---|
| Apr 1, 26 | Evans John M. | sell | 30,078 |
| Apr 1, 26 | Simon Amy | sell | 6,700 |
| Apr 1, 26 | Cavanagh Bethany J | sell | 3,242 |
| Apr 1, 26 | Bellon Christine | sell | 5,956 |
| Apr 1, 26 | Ciaramella Giuseppe | sell | 11,810 |
| Mar 31, 26 | Bellon Christine | other | 20,000 |
| Mar 31, 26 | Cavanagh Bethany J | other | 20,000 |
| Mar 31, 26 | Simon Amy | other | 31,750 |
| Mar 31, 26 | Emany Sravan Kumar | other | 31,750 |
| Mar 31, 26 | Ciaramella Giuseppe | other | 40,000 |
Our BEAM Coverage
We haven't published any research on BEAM yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate BEAM Report →